Marit Aaserud

Marit Aaserud

Auto-generated profile, based on publicly available information

Marit Aaserud

Department of Pathology, Oslo University Hospital, P.O. Box 4953 Nydalen, N-0424 Oslo, Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TLTonje Lien
Tonje Lien
HOHege Oma Ohnstad
Hege Oma Ohnstad
OLOle Christian Lingjærde
Ole Christian Lingjærde
JVJohan Vallon-Christersson
Johan Vallon-Christersson
MAMarit Aaserud
Marit Aaserud
TSTherese Sørlie
Therese Sørlie
The PAM50 gene expression subtypes and the associated risk of recurrence (ROR) score are used to predict the risk of recurrence and the benefits of adjuvant therapy in early-stage breast cancer. The Prosigna assay includes the PAM50 subtypes along with their clinicopathological features, and is approved for treatment recommendations for adjuvant hormonal therapy and chemotherapy in hormone-receptor-positive early breast cancer. The Prosigna test utilizes RNA extracted from macrodissected tumor cells obtained from formalin-fixed, paraffin-embedded (FFPE) tissue sections. However, RNA extracted from fresh-frozen (FF) bulk tissue without macrodissection is widely used for research purposes, and yields high-quality RNA for downstream analyses. To investigate the impact of the sample preparation approach on ROR scores, we analyzed 94 breast carcinomas included in an observational study that had available gene expression data from macrodissected FFPE tissue and FF bulk tumor tissue, along with the clinically approved Prosigna scores for the node-negative, hormone-receptor-positive, HER2-negative cases (n = 54). ROR scores were calculated in R; the resulting two sets of scores from FFPE and FF samples were compared, and treatment recommendations were evaluated. Overall, ROR scores calculated based on the macrodissected FFPE tissue were consistent with the Prosigna scores. However, analyses from bulk tissue yielded a higher proportion of cases classified as normal-like; these were samples with relatively low tumor cellularity, leading to lower ROR scores. When comparing ROR scores (low, intermediate, and high), discordant cases between the two preparation approaches were revealed among the luminal tumors; the recommended treatment would have changed in a minority of cases.

23 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TLTonje Lien
Tonje Lien
HOHege Oma Ohnstad
Hege Oma Ohnstad
OLOle Christian Lingjærde
Ole Christian Lingjærde
JVJohan Vallon-Christersson
Johan Vallon-Christersson
MAMarit Aaserud
Marit Aaserud
TSTherese Sørlie
Therese Sørlie
There are two text errors in the original publication